Spinal muscular atrophy (SMA) is an autosomal recessive disease characteriz
ed by degeneration of the anterior horn cells of the spinal cord, leading t
o muscular paralysis with muscular atrophy. No effective treatment of this
disorder is presently available. Studies of the correlation between disease
severity and the amount of survival motor neuron (SMN) protein have shown
an inverse relationship. We report that sodium butyrate effectively increas
es the amount of exon 7-containing SMN protein in SMA lymphoid cell lines b
y changing the alternative splicing pattern of exon 7 in the SMN2 gene. In
vivo, sodium butyrate treatment of SMA-like mice resulted in increased expr
ession of SMN protein in motor neurons of the spinal cord and resulted in s
ignificant improvement of SMA clinical symptoms. Oral administration of sod
ium butyrate to intercrosses of heterozygous pregnant knockout-transgenic S
MA-like mice decreased the birth rate of severe types of SMA-like mice, and
SMA symptoms were ameliorated for all three types of SMA-like mice. These
results suggest that sodium butyrate may be an effective drug for the treat
ment of human SMA patients.